Touchlight is proud to announce a strategic partnership with SVF Vaccines to progress SVF’s innovative Hepatitis B/D vaccine into clinical development.
Touchlight and New England Biolabs launch the EnClose™ Cell‑free dbDNA™ Synthesis Kit, enabling rapid, scalable, cell‑free production of high‑purity DNA for next‑generation mRNA, gene therapy, and vector development.
Touchlight today announced the expansion of its groundbreaking mbDNA™ platform with the introduction of three new circular DNA architectures: sscDNA, hsscDNA, and dscDNA.
Touchlight announced today that its proprietary z- dbDNA™ technology is to be utilised as a critical starting material in the manufacture of a cutting-edge gene therapy for a US-based clinical…
Touchlight, a pioneering leader in DNA manufacturing technologies, has been named the 2025 FOYA Category Winner for Innovation in the International Society for Pharmaceutical Engineering (ISPE) Facility of the Year…
Touchlight Introduces mbDNA™: A “best-in-class" circular single stranded DNA (ssDNA) platform enabling superior gene editing Published: 30 July 2025Touchlight, a pioneer in cell-free DNA innovation, is proud to announce the…
Touchlight Wins ISPE Facility of the Year Award for Innovation, Recognised for Revolutionary dbDNA™ Manufacturing at Morelands Facility Published: 12 May 2025Touchlight, a pioneering leader in synthetic DNA technology, is…
Touchlight Appoints Industry Leader Will Downie as Adviser to Support Strategic Growth in Synthetic DNA Platforms Published: 27 January 2025 Touchlight Genetics, in partnership with the National Physical Laboratory (NPL)…
20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project Published: 18 April 2023 Curia collaborates with Touchlight to expand its mRNA manufacturing offering to enable access to…
Touchlight announces first FDA clearance of an IND utilising doggybone DNA Published: 28 February 2023 Enzymatic doggybone DNA material used in GMP production of a cell therapy by a US-based…